Relay Therapeutics, Inc. Operating Cash Flow
Relay Therapeutics, Inc. (RLAY) reported Operating Cash Flow of -$105.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$54.11M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$51.11M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$44.87M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$62.12M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$235.46M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$249.11M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$300.32M.
- Relay Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$229.49M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$54.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$105.22M 10-Q · filed 2026-08-06 | -$150.09M derived: sum of 3 quarters · filed 2026-08-06 | -$212.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$51.11M 10-Q · filed 2026-05-05 | -$95.98M derived: sum of 2 quarters · filed 2026-05-05 | -$158.10M derived: sum of 3 quarters · filed 2026-05-05 | -$213.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$44.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$106.98M derived: sum of 2 quarters · filed 2026-02-26 | -$162.25M derived: sum of 3 quarters · filed 2026-08-06 | -$235.46M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$62.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$117.38M derived: sum of 2 quarters · filed 2026-08-06 | -$190.59M 10-Q · filed 2025-11-06 | -$248.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$55.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$128.47M 10-Q · filed 2026-08-06 | -$186.34M derived: sum of 3 quarters · filed 2026-08-06 | -$261.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$73.21M 10-Q · filed 2026-05-05 | -$131.08M derived: sum of 2 quarters · filed 2026-05-05 | -$206.16M derived: sum of 3 quarters · filed 2026-05-05 | -$271.99M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$57.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$132.95M derived: sum of 2 quarters · filed 2026-02-26 | -$198.78M derived: sum of 3 quarters · filed 2026-02-26 | -$249.11M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$75.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$140.92M derived: sum of 2 quarters · filed 2025-11-06 | -$191.24M 10-Q · filed 2025-11-06 | -$280.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$65.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$116.16M 10-Q · filed 2025-08-07 | -$205.34M derived: sum of 3 quarters · filed 2026-02-26 | -$280.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$50.32M 10-Q · filed 2025-05-05 | -$139.51M derived: sum of 2 quarters · filed 2026-02-26 | -$214.91M derived: sum of 3 quarters · filed 2026-02-26 | -$283.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$89.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$164.59M derived: sum of 2 quarters · filed 2026-02-26 | -$233.19M derived: sum of 3 quarters · filed 2026-02-26 | -$300.32M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$75.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$144.00M derived: sum of 2 quarters · filed 2024-11-06 | -$211.13M 10-Q · filed 2024-11-06 | -$268.21M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$68.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$135.73M 10-Q · filed 2024-08-06 | -$192.81M derived: sum of 3 quarters · filed 2025-02-26 | -$258.95M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$67.13M 10-Q · filed 2024-05-02 | -$124.21M derived: sum of 2 quarters · filed 2025-02-26 | -$190.35M derived: sum of 3 quarters · filed 2025-02-26 | -$247.45M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$57.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$123.22M derived: sum of 2 quarters · filed 2025-02-26 | -$180.32M derived: sum of 3 quarters · filed 2025-02-26 | -$229.49M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$66.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$123.24M derived: sum of 2 quarters · filed 2023-11-02 | -$172.41M 10-Q · filed 2023-11-02 | -$212.12M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$57.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$106.27M 10-Q · filed 2023-08-08 | -$145.97M derived: sum of 3 quarters · filed 2024-02-22 | -$199.17M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$49.17M 10-Q · filed 2023-05-04 | -$88.88M derived: sum of 2 quarters · filed 2024-02-22 | -$142.08M derived: sum of 3 quarters · filed 2024-02-22 | -$170.22M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$39.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$92.91M derived: sum of 2 quarters · filed 2024-02-22 | -$121.05M derived: sum of 3 quarters · filed 2024-02-22 | -$74.41M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$53.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$81.34M derived: sum of 2 quarters · filed 2022-11-03 | -$34.70M 10-Q · filed 2022-11-03 | -$69.97M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$28.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $18.50M 10-Q · filed 2022-08-04 | -$16.77M derived: sum of 3 quarters · filed 2023-02-23 | -$40.81M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $46.64M 10-Q · filed 2022-05-05 | $11.37M derived: sum of 2 quarters · filed 2023-02-23 | -$12.67M derived: sum of 3 quarters · filed 2023-02-23 | -$33.52M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$35.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$59.31M derived: sum of 2 quarters · filed 2023-02-23 | -$80.16M derived: sum of 3 quarters · filed 2023-02-23 | -$102.49M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$24.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$44.88M derived: sum of 2 quarters · filed 2021-11-10 | -$67.22M 10-Q · filed 2021-11-10 | -$89.98M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$20.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$43.18M 10-Q · filed 2021-08-12 | -$65.94M derived: sum of 3 quarters · filed 2022-02-24 | -$83.44M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$22.33M 10-Q · filed 2021-05-13 | -$45.09M derived: sum of 2 quarters · filed 2022-02-24 | -$62.60M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | -$22.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$40.26M derived: sum of 2 quarters · filed 2022-02-24 | -$66.13M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$17.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$43.37M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$25.87M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |